Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

Completed · Phase 4

Conditions studied: Glaucoma

In brief

To evaluate the IOP-lowering efficacy of bimatoprost 0.03% in patients found to be low-responders to latanoprost therapy.

Key facts

Study ID

NCT00347841

Run by

Innovative Medical

Last updated by the study team

2007-06-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• · Male or female > 18 years of age
• Documented low-responder to latanoprost therapy as delineated in the outline above.
• Diagnosis of open-angle glaucoma or ocular hypertension
• Ability to provide informed consent and likely to complete all study visits

You may not qualify if…

• · Known contraindication to bimatoprost or any component of any study medication
• Uncontrolled systemic disease
• Active ocular disease other than glaucoma or ocular hypertension
• Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear solutions will be permitted)
• History of intraocular surgery within the last 3 months

Where it is running

• Dr. Noecker — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.